For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250130:nRSd3597Va&default-theme=true
RNS Number : 3597V Ondine Biomedical Inc. 30 January 2025
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
CA68234M2058
Issuer Name
ONDINE BIOMEDICAL INC
UK or Non-UK Issuer
Non-UK
2. Reason for Notification
Other
Comments
New shares were issued diluting ownership.
3. Details of person subject to the notification obligation
Name
Carolyn Cross
City of registered office (if applicable)
Vancouver
Country of registered office (if applicable)
Canada
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the
notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
29-Jan-2025
6. Date on which Issuer notified
29-Jan-2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached 26.715201 0.000000 26.715201 118,091,377
Position of previous notification (if applicable) 29.230197 0.000000 29.230197 118,091,377
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1)
CA68234M2058 65,884,085 52,207,292 14.904615 11.810585%
Sub Total 8.A 118,091,377 26.715201
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is % of voting rights
exercised/converted
Sub Total 8.B1
8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))
Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights
Sub Total 8.B2
9. Information in relation to the person subject to the notification
obligation
2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add additional
rows as necessary)
Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher Total of both if it equals or is higher than the notifiable threshold
than the notifiable threshold
Carolyn Cross Carolyn Cross 26.715201 26.715201
Carolyn Cross 0902337 B.C. Ltd (wholly owned by Carolyn Cross) 26.715201 26.715201
Carolyn Cross Vencourt Capital Ltd (wholly owned by Carolyn Cross) 26.715201 26.715201
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
12. Date of Completion
30-Jan-2025
13. Place Of Completion
Vancouver, Canada
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END HOLDZGFMNGRGKZM